BEIJING – As the world continues to tackle infectious diseases, the role of vaccine manufacturers in protecting global health is extremely important.
As an Iranian journalist and representative of the Tehran era, I had the privilege of visiting Sinovac Biotech, a well-known Chinese vaccine maker.
The event, entitled “Sinovac Open Day at International Media for International Media,” provided important insights into the company’s operations and its role in improving health worldwide.
During the tour, Sinovac researchers highlighted their commitment to developing cutting-edge vaccines spanning diseases such as hepatitis, flu, hand, foot and mouth diseases (HFMD). The company’s cutting-edge facilities and strict quality control processes reflect its commitment to producing safe, effective and accessible vaccines.
One of the most striking aspects of Sinovac’s work is its focus on global health equity. Unlike the profit-first drug giant, Sinovac is actively involved in technology transfers and local production partnerships. This approach not only accelerates vaccine availability, but also enhances global health resilience by building manufacturing capacity in the regions where it needs it most.
Unlike the global drug giant that prioritizes profits, Sinovac is actively involved in technology transfers and local production partnerships
During my visit, I was concerned with the company’s achievements, Sinovac Life Science Co., Ltd. asked Ying Zhang, assistant general manager of the company.
She highlighted Sinovac’s commitment to providing globally accessible and effective healthcare solutions. Ying pointed out that Sinovac developed a vaccine with the aim of protecting people around the world from illness. Ying said that Sinovac will provide high-quality products globally and ensure that future increases in individuals will benefit from vaccination. She said that Beijing’s support is a major achievement for Sinovac.
We also spoke with Pearson Liu, Senior Assistant Chief Business Officer of Sinovac Holding Group Co., Ltd. He said Sinovac’s main mission is to supply vaccines globally to eradicate human diseases, and the company is to stick to this commitment.
Sinovac’s product portfolio includes vaccines against Covid-19. Coronavac®, a Covid-19 vaccine, is approved for use in more than 60 countries and regions around the world.
Sinovac independently developed seven vaccines, either China’s first or the world’s first vaccine product.
The company has not spared efforts to protect human health under its mission to “supply vaccines to eliminate human diseases.”
As a journalist in Iran, a country that has benefited from vaccine cooperation with China, I was particularly impressed by Sinovak’s willingness to share knowledge and resources. In a world where geopolitical tensions often hinder scientific cooperation, Shinovac’s efforts exist as evidence of the power of solidarity in overcoming health crises.
Sinovac’s work, coupled with his commitment to global equity, exemplifies how scientific innovation can pave the way for a healthier future. By prioritizing accessibility and collaboration, the company not only saves today’s lives, but also lays the foundation for a world where preventable diseases are things of the past.
As international journalists, we have a responsibility to emphasize such efforts. Because unity and shared knowledge are our strongest weapons in the fight against the pandemic.